IN2012DN02379A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02379A
IN2012DN02379A IN2379DEN2012A IN2012DN02379A IN 2012DN02379 A IN2012DN02379 A IN 2012DN02379A IN 2379DEN2012 A IN2379DEN2012 A IN 2379DEN2012A IN 2012DN02379 A IN2012DN02379 A IN 2012DN02379A
Authority
IN
India
Prior art keywords
pharmaceutically acceptable
liquid vehicle
acceptable liquid
suspension formulation
oral suspension
Prior art date
Application number
Other languages
English (en)
Inventor
Te Ofilo Cardoso De Vasconcelos
Lima Ricardo Jorge Dos Santos
Costa Rui Cerdeira De Campos
Barrocas Pedro Miguel Da Costa
Pereira Ligia Sofia De Castro
Original Assignee
Bial Portela & C A Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bial Portela & C A Sa filed Critical Bial Portela & C A Sa
Publication of IN2012DN02379A publication Critical patent/IN2012DN02379A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
IN2379DEN2012 2009-09-10 2010-09-10 IN2012DN02379A (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24119509P 2009-09-10 2009-09-10
PCT/PT2010/000038 WO2011031176A1 (en) 2009-09-10 2010-09-10 Oral suspension formulations of esclicarbazepine acetate

Publications (1)

Publication Number Publication Date
IN2012DN02379A true IN2012DN02379A (de) 2015-08-21

Family

ID=43037794

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2379DEN2012 IN2012DN02379A (de) 2009-09-10 2010-09-10

Country Status (13)

Country Link
US (2) US20130040939A1 (de)
EP (1) EP2475357A1 (de)
JP (1) JP2013504569A (de)
KR (1) KR20120094473A (de)
CN (1) CN102612359A (de)
AR (1) AR078283A1 (de)
AU (1) AU2010293105A1 (de)
BR (1) BR112012005254A2 (de)
CA (1) CA2773249A1 (de)
IN (1) IN2012DN02379A (de)
MX (1) MX2012002831A (de)
RU (1) RU2012113844A (de)
WO (1) WO2011031176A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
UA106384C2 (ru) 2009-07-27 2014-08-26 БИАЛ-ПОРТЕЛА энд КА., С.А. ПРИМЕНЕНИЕ ПРОИЗВОДНЫХ 5H-ДИБЕНЗ/б,ф/АЗЕПИН-5-КАРБОКСАМИДА ДЛЯ ЛЕЧЕНИЯ ФИБРОМИАЛГИИ
US9750747B2 (en) 2011-08-26 2017-09-05 Bail-Portela & Ca, S.A. Treatments involving eslicarbazepine acetate or eslicarbazepine
GB201306095D0 (en) * 2013-04-04 2013-05-22 Bial Portela & Ca Sa New treatments
JP6122815B2 (ja) * 2014-02-20 2017-04-26 ライオン株式会社 経口製剤及びその製造方法
JP6786240B2 (ja) * 2016-03-31 2020-11-18 小林製薬株式会社 粘性経口組成物
WO2019058353A1 (en) * 2017-09-25 2019-03-28 Jubilant Generics Limited MODIFIED RELEASE SUSPENSION OF ESLICARBAZEPINE
WO2019058354A1 (en) * 2017-09-25 2019-03-28 Jubilant Generics Limited SUSPENSION OF ESLICARBAZÉPINE
US11318145B2 (en) * 2018-09-25 2022-05-03 Jubilant Generics Limited Eslicarbazepine suspension

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8618847D0 (en) * 1986-08-01 1986-09-10 Smith Kline French Lab Pharmaceutical formulations
PT721335E (pt) * 1993-10-01 2005-11-30 Roche Palo Alto Llc Suspensoes orais em altas doses de micofenolato de mofetil
US6184220B1 (en) * 1998-03-27 2001-02-06 Boehringer Ingelheim Pharma Kg Oral suspension of pharmaceutical substance
GB9930058D0 (en) * 1999-12-20 2000-02-09 Novartis Ag Organic compounds
US20020028794A1 (en) * 2000-07-21 2002-03-07 Brubaker Greg Allen Megestrol acetate suspension
US6510799B2 (en) * 2001-07-02 2003-01-28 Magna Force, Inc. Apparatus, systems and methods for levitating and moving objects
US7300670B2 (en) * 2002-04-03 2007-11-27 Unilab Pharmatech, Ltd. Oral suspension formulation
CA2486553C (en) * 2002-06-17 2012-01-10 Taro Pharmaceuticals U.S.A., Inc. Ibuprofen suspension
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
US7118508B2 (en) * 2004-07-28 2006-10-10 General Motors Corporation Planetary transmissions having three interconnected gear members and clutched input members
WO2006018814A2 (en) * 2004-08-16 2006-02-23 Ranbaxy Laboratories Limited Oral liquid suspensions of metaxalone
EP2384755A1 (de) 2005-05-06 2011-11-09 Bial-Portela & CA, S.A. Esclicarbazepin-Acetat und Verwendungsverfahren
US20060252745A1 (en) * 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
WO2007007182A2 (en) * 2005-07-08 2007-01-18 Aurobindo Pharma Limited Solid and liquid dosage forms of an antiepileptic agent

Also Published As

Publication number Publication date
MX2012002831A (es) 2012-05-08
AU2010293105A1 (en) 2012-04-05
US20130040939A1 (en) 2013-02-14
WO2011031176A1 (en) 2011-03-17
AU2010293105A8 (en) 2012-07-19
US20180256594A1 (en) 2018-09-13
BR112012005254A2 (pt) 2016-03-15
CN102612359A (zh) 2012-07-25
AR078283A1 (es) 2011-10-26
CA2773249A1 (en) 2011-03-17
RU2012113844A (ru) 2013-10-20
KR20120094473A (ko) 2012-08-24
EP2475357A1 (de) 2012-07-18
JP2013504569A (ja) 2013-02-07

Similar Documents

Publication Publication Date Title
IN2012DN02379A (de)
TN2012000195A1 (en) Solid dispersion of rifaximin
EP2442856A4 (de) Anordnung für medikamentenbehälterhalter
AU2010260569A8 (en) Medicament container holder arrangement
EP2459112B8 (de) Mundpflegevorrichtung
EP2396070A4 (de) Wirkstofffreisetzung mit hydrogel-plugs
IL205160A0 (en) Oral dosage forms comprising licarbazepine acetate
PL2337607T3 (pl) Urządzenie do podawania leku do ucha wewnętrznego
EP2360173A4 (de) Zytotoxisches t-zell-epitop-peptid für sars-coronavirus und verwendung
IL217500A0 (en) Tetrazole derivatives, their preparartion and pharmaceutical compositions containing them
EP2481682A4 (de) Arzneimittelpackungsbeutel und folie für diese beutel
EP2422192B8 (de) Referenzelektrode und kombinierte elektrode
WO2010148314A3 (en) Preparation of esomeprazole and its pharmaceutically acceptable salts
SG2013089776A (en) Combined drug administration
ZA201204670B (en) Seven-membered ring compound and pharmaceutical use therefor
EP2509708B8 (de) Siliziumphosphat und membran damit
IL220839B (en) History of 3-phenylamino-9-azabicyclo[1.3.3]nonane and pharmaceutical preparations containing them
ZA201005396B (en) 17-hydroxy-19-nor-21-carboxylic acid-steroid y-lactone derivative,use thereof,and medicament containing the derivative
AU2014233620B2 (en) Oral care system
AU2008904116A0 (en) Capsule Delivery Instrument
AU2009904184A0 (en) The Delivery of Medical Prescriptions
AU2009903559A0 (en) An administration set flow condition monitor
AU2009904280A0 (en) Dental container
GB0906003D0 (en) Oral drug formulation
LT2009004A (en) New combination of active ingredients containing a non steroidal antiimplamatotory drug and a colchicoside derivative